Overview of the speech at the II Joint Congress of NODGO and RODO: “For the first time in Russia. Clinical recommendations for infantile hemangiomas”

1. ISSVA classification for vascular anomalies. Approved at the 20th ISSVA Workshop, Melbourne, April 2014, last revision, May, 2018. Available online: https://www.issva.org/UserFiles/file/ISSVA-Classification-2018.pdf. Accessed on October 22, 2021.

2. Krowchuk D.P., Frieden I.J., Mancini A.J., Darrow D.H., Blei F., Greene A.K., Annam A., Baker C.N., Frommelt P.C., Hodak A., Pate B.M., Pelletier J.L., Sandrock D., Weinberg S.T., Whelan M.A., SUBCOMMITTEE ON THE MANAGEMENT OF INFANTILE HEMANGIOMAS. Clinical practice guideline for the management of infantile hemangiomas. Pediatrics. 2019;143(1):e20183475. doi: 10.1542/peds.2018-3475.

3. Kotlukova N.P., Belysheva T.S., Valiev T.T., Konstantinova N.K., Telezhnikova N.D., Lavrova T.R. Interdisciplinary approach to the treatment of infant hemangioma. Pediatriya. Zhurnal im. G.N. Speranskogo. = Pediatrics named after G.N. Speransky. 2021;100(3):174–82. (In Russ.)

4. Satterfield K.R., Chamber C.B. Current treatment and management of infantile hemangiomas. Surv Opthalmol. 2019:64(5):608–18. doi: 10.1016/j.survophthal.2019.02.005.

5. Инструкция по медицинскому применению препарата Гемангиол.

6. Sans V., Dumas de la Roque E., Berge J., Grenier N., Boralevi F., Mazereeuw-Hautier J., Lipsker D., Dupuis E., Ezzedine K., Vergnes P., Taïeb A., Léauté-Labrèze C. Propranolol for Severe Infantile Hemangiomas: Follow-Up Report. Pediatrics. 2009;124(3):e423–31. doi: 10.1542/peds.2008-3458.

7. Thoumazet F., Leaute-Labreze C., Colin J., Mortemousque B. Efficacy of systemic propanolol for severe infantile haemangioma of the orbit and eyelid: a case study of eight patients. Br J Ophthalmol. 2012;96(3):370–4. doi: 10.1136/bjophthalmol-2011-300047.